Journal
TRANSPLANT INTERNATIONAL
Volume 23, Issue 3, Pages 259-265Publisher
WILEY
DOI: 10.1111/j.1432-2277.2009.00984.x
Keywords
culture; function; glucagon; islet; pancreas; peptide
Categories
Funding
- Swiss National Science Foundation
- Alberta Heritage Foundation for Medical Research (AHFMR)
- Canadian Institutes for Health Research
Ask authors/readers for more resources
The culture of human islets is associated with approximately 10-20% islet loss, occasionally preventing transplantation. Preconditioning of the islets to improve postculture yields would be of immediate benefit, with the potential to increase both the number of transplanted patients and their metabolic reserve. In this study, the effect of liraglutide, a long-acting human glucagon-like peptide 1 analogue, on cultured human islets was examined. Culture with liraglutide (1 mu mol/l) was associated with a preservation of islet mass (significantly more islets at 24 and 48 h, compared to control; P <= 0.05 at 24 and 48 h) and with the presence of larger islets (P <= 0.05 at 48 h). These observations were supported by reduced apoptosis rates after 24 h of treatment. We also demonstrated that human islet engraftment is improved in C57Bl/6-RAG(-/-) mice treated with liraglutide 200 mu g/kg sc twice daily (P <= 0.05), suggesting that liraglutide should be continued after transplantation. Overall, these data demonstrate the beneficial effect of liraglutide on cultured human islets, preserving islet mass. They support the design of clinical studies looking at the effect of liraglutide in clinical islet transplantation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available